DTech Liquidating

DTech Liquidating Gross Margin

Delisted

The Gross Margin of DTech Liquidating (DMTKQ) as of Nov 21, 2026 is 1.80 %. In the previous year, Gross Margin was 4.48 % — a change of -59.69% (lower).

Gross Margin

1.80 %

YoY

-59.69%

Last updated:

Gross Margin of DTech Liquidating is 2023 1.80 % . Gross Margin of DTech Liquidating was 2022 4.48 % . It decreases by -59.69% lower compared to the previous year.

For DTech Liquidating, the gross margin of 1.8% is broadly stable versus 1.8% a few years ago.

The DTech Liquidating Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
1.79 USD
Jan 1, 2020
-1.70 USD
Jan 1, 2021
10.73 USD
Jan 1, 2022
4.48 USD
Jan 1, 2023
1.80 USD
The DTech Liquidating Gross Margin history
YEARGross MarginYoY
1.80 %-59.69%
4.48 %-58.27%
10.73 %-731.78%
-1.70 %-195.08%
1.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Gross Margin of DTech Liquidating is 1.80 % in 2023.

Gross Margin of DTech Liquidating changed from 4.48 % to 1.80 %, representing a -59.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's DTech Liquidating with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — DTech Liquidating

All Key Metrics — DTech Liquidating